CJC-1295 vs Deslorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.
Full profileDeslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profile| CJC-1295 | Deslorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29 | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH |
| Evidence | Research-stage | Research-stage |
| Dosing range | 100mcg–300mcg mcg, once daily (Mod GRF) or twice weekly (DAC version) | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset |
| Administration | Subcutaneous injection (most common), Intramuscular injection | Subcutaneous implant (veterinary), Subcutaneous injection |
| Key side effects | Water retention (especially early in protocol), Tingling or numbness in extremities, Injection site redness, Flushing (transient, shortly after injection) | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: CJC-1295 — Subcutaneous injection (most common), Intramuscular injection; Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection.
- Frequency: CJC-1295 is typically once daily (Mod GRF) or twice weekly (DAC version); Deslorelin is Daily SC for continuous suppression; single or short course for pituitary reset.
How each works
CJC-1295
Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.